Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Cancer Insight, LLC
Sponsor:
Collaborators:
Genentech, Inc.
Galena Biopharma, Inc.
Information provided by (Responsible Party):
George E. Peoples, Cancer Insight, LLC
ClinicalTrials.gov Identifier:
NCT01570036
First received: March 25, 2012
Last updated: November 27, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)